Opaleye Management Inc. 13D and 13G filings for Eton Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-09-12 4:05 pm Purchase |
2024-09-09 | 13G | Eton Pharmaceuticals, Inc. ETON |
Opaleye Management Inc. | 2,722,500 10.340% |
197,613 (+7.83%) |
Filing |
| 2024-02-09 4:05 pm Purchase |
2023-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON |
Opaleye Management Inc. | 2,524,887 9.840% |
354,887 (+16.35%) |
Filing |
| 2023-01-20 4:53 pm Sale |
2022-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON |
Opaleye Management Inc. | 2,170,000 8.580% |
-215,000 (-9.01%) |
Filing |
| 2022-01-24 4:05 pm Sale |
2021-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON |
Opaleye Management Inc. | 2,385,000 9.690% |
-1,307,700 (-35.41%) |
Filing |
| 2021-06-17 4:40 pm Purchase |
2020-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON |
Opaleye Management Inc. | 3,692,700 15.070% |
52,700 (+1.45%) |
Filing |
| 2020-05-26 11:09 am Purchase |
2020-05-14 | 13G | Eton Pharmaceuticals, Inc. ETON |
Opaleye Management Inc. | 2,625,000 10.270% |
285,000 (+12.18%) |
Filing |